HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation
Oncology Research · 2025
DOI: 10.32604/or.2024.055866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Yuezhou Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Disease Progression, Heterogeneous-Nuclear Ribonucleoprotein Group C, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zitieren
APA
Zhang, Y., Zhang, Z., Dong, J., & Liu, C. (2025). HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation. Oncology Research. https://doi.org/10.32604/or.2024.055866
Vancouver
Zhang Y, Zhang Z, Dong J, Liu C. HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation. Oncology Research. 2025. doi:10.32604/or.2024.055866
BibTeX
@article{Zhang2025,
author = {Zhang, Yuezhou and Zhang, Zhao and Dong, Jinxin and Liu, Changan},
title = {HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2024.055866}
}
EUVIMED